Endpoints News reports that the agreement covers a trispecific T-cell engager for multiple myeloma and marks GSK’s second deal with the Chinese biotech.
GSK is paying up to $750 million for Chimagen’s trispecific T-cell engager for multiple myeloma, a blood cancer, Endpoints News reports. The agreement is GSK’s second T-cell engager deal with the Chinese biotech.
2.9K
1 post, first seen 19h ago
Endpoints News reports that the agreement covers a trispecific T-cell engager for multiple myeloma and marks GSK’s second deal with the Chinese biotech.
GSK is paying up to $750 million for Chimagen’s trispecific T-cell engager for multiple myeloma, a blood cancer, Endpoints News reports. The agreement is GSK’s second T-cell engager deal with the Chinese biotech.
Endpoints News@endptsGSK is paying up to $750M for Chimagen's trispecific T cell engager, its second deal with the Chinese biotech, this time in multiple myeloma.
Not enough discussion yet.
No sentiment analysis available yet.
Endpoints News@endptsGSK is paying up to $750M for Chimagen's trispecific T cell engager, its second deal with the Chinese biotech, this time in multiple myeloma.
Not enough discussion yet.
No sentiment analysis available yet.
—
Not ranked yet
—
Not ranked yet